OBJECTIVE: To characterize the results of surgery for gastrointestinal stromal tumor (GIST) in the pre and post-imatinib eras at a single institution and to identify current prognostic clinicopathologic factors. BACKGROUND: Imatinib has radically changed the management of GIST, yet the magnitude of impact on outcome across the spectrum of GIST presentation and relevance of historical prognostic factors are not well defined. METHODS: We retrospectively analyzed 1000 patients who underwent surgery for GIST at our institution from 1982 to 2016. Patients were stratified by presentation status as primary tumor only (PRIM), primary with synchronous metastasis (PRIM + MET), or metachronous recurrence/metastases (MET), and also imatinib era (before and after it became available). Cox proportional-hazard models and Kaplan-Meier methods were used to model and estimate overall survival (OS) and recurrence-free survival (RFS). RESULTS: OS was longer in the imatinib era compared with the pre-imatinib era in each presentation group, including in Miettinen high-risk primary tumors. Among PRIM patients from the pre-imatinib era, tumor site, size, and mitotic rate were independently associated with OS and RFS on multivariate analysis. PRIM patients in the imatinib era who received imatinib (neoadjuvant and/or adjuvant) had higher risk tumors, but after adjusting for treatment, only size >10 cm remained independently prognostic of RFS [hazard ratio (HR) 3.85, 95% confidence interval (CI) 2.00-7.40, P < 0.0001) and OS (HR 3.37, 95% CI 1.60-7.13, P = 0.001)]. CONCLUSIONS: Patients treated in the imatinib era had prolonged OS across all presentations. In the imatinib era, among site, size, and mitotic rate, high-risk features were associated with treatment with the drug, but only size >10 cm correlated with outcome. Imatinib should still be prescribed for patients with high-risk features.
OBJECTIVE: To characterize the results of surgery for gastrointestinal stromal tumor (GIST) in the pre and post-imatinib eras at a single institution and to identify current prognostic clinicopathologic factors. BACKGROUND: Imatinib has radically changed the management of GIST, yet the magnitude of impact on outcome across the spectrum of GIST presentation and relevance of historical prognostic factors are not well defined. METHODS: We retrospectively analyzed 1000 patients who underwent surgery for GIST at our institution from 1982 to 2016. Patients were stratified by presentation status as primary tumor only (PRIM), primary with synchronous metastasis (PRIM + MET), or metachronous recurrence/metastases (MET), and also imatinib era (before and after it became available). Cox proportional-hazard models and Kaplan-Meier methods were used to model and estimate overall survival (OS) and recurrence-free survival (RFS). RESULTS: OS was longer in the imatinib era compared with the pre-imatinib era in each presentation group, including in Miettinen high-risk primary tumors. Among PRIM patients from the pre-imatinib era, tumor site, size, and mitotic rate were independently associated with OS and RFS on multivariate analysis. PRIM patients in the imatinib era who received imatinib (neoadjuvant and/or adjuvant) had higher risk tumors, but after adjusting for treatment, only size >10 cm remained independently prognostic of RFS [hazard ratio (HR) 3.85, 95% confidence interval (CI) 2.00-7.40, P < 0.0001) and OS (HR 3.37, 95% CI 1.60-7.13, P = 0.001)]. CONCLUSIONS: Patients treated in the imatinib era had prolonged OS across all presentations. In the imatinib era, among site, size, and mitotic rate, high-risk features were associated with treatment with the drug, but only size >10 cm correlated with outcome. Imatinib should still be prescribed for patients with high-risk features.
Authors: Martin D McCarter; Cristina R Antonescu; Karla V Ballman; Robert G Maki; Peter W T Pisters; George D Demetri; Charles D Blanke; Margaret von Mehren; Murray F Brennan; Linda McCall; David M Ota; Ronald P DeMatteo Journal: J Am Coll Surg Date: 2012-07 Impact factor: 6.113
Authors: Mark Fairweather; Vinod P Balachandran; George Z Li; Monica M Bertagnolli; Cristina Antonescu; William Tap; Samuel Singer; Ronald P DeMatteo; Chandrajit P Raut Journal: Ann Surg Date: 2018-08 Impact factor: 12.969
Authors: Christopher L Corless; Karla V Ballman; Cristina R Antonescu; Violetta Kolesnikova; Robert G Maki; Peter W T Pisters; Martin E Blackstein; Charles D Blanke; George D Demetri; Michael C Heinrich; Margaret von Mehren; Shreyaskumar Patel; Martin D McCarter; Kouros Owzar; Ronald P DeMatteo Journal: J Clin Oncol Date: 2014-03-17 Impact factor: 44.544
Authors: Maha Alkhuziem; Adam M Burgoyne; Paul T Fanta; Chih-Min Tang; Jason K Sicklick Journal: J Natl Compr Canc Netw Date: 2017-05 Impact factor: 11.908
Authors: Samuel Singer; Brian P Rubin; Marcia L Lux; Chang-Jie Chen; George D Demetri; Christopher D M Fletcher; Jonathan A Fletcher Journal: J Clin Oncol Date: 2002-09-15 Impact factor: 44.544
Authors: Burton L Eisenberg; Jonathan Harris; Charles D Blanke; George D Demetri; Michael C Heinrich; James C Watson; John P Hoffman; Scott Okuno; John M Kane; Margaret von Mehren Journal: J Surg Oncol Date: 2009-01-01 Impact factor: 3.454
Authors: Eva Wardelmann; Sabine Merkelbach-Bruse; Katharina Pauls; Nadja Thomas; Hans-Ulrich Schildhaus; Thomas Heinicke; Nicola Speidel; Torsten Pietsch; Reinhard Buettner; Daniel Pink; Peter Reichardt; Peter Hohenberger Journal: Clin Cancer Res Date: 2006-03-15 Impact factor: 12.531
Authors: Ping Chi; Yu Chen; Lei Zhang; Xingyi Guo; John Wongvipat; Tambudzai Shamu; Jonathan A Fletcher; Scott Dewell; Robert G Maki; Deyou Zheng; Cristina R Antonescu; C David Allis; Charles L Sawyers Journal: Nature Date: 2010-10-03 Impact factor: 49.962
Authors: Michael J Cavnar; Kenneth Seier; Mithat Gönen; Christina Curtin; Vinod P Balachandran; William D Tap; Cristina R Antonescu; Sam Singer; Ronald P DeMatteo Journal: J Gastrointest Surg Date: 2020-11-09 Impact factor: 3.267
Authors: Mariarita Tarallo; Cristina Carruezzo; Filippo Maria Dentice Di Accadia; Antonella Del Gaudio; Damiano Caruso; Michela Polici; Daniele Crocetti; Umberto Costi; Andrea Polistena; Francesco Panzuto; Andrea Laghi; Giuseppe Cavallaro; Enrico Fiori Journal: Front Surg Date: 2022-05-20
Authors: Elisabeth M P Steeghs; Hans Gelderblom; Vincent K Y Ho; Quirinus J M Voorham; Stefan M Willems; Katrien Grünberg; Marjolijn J L Ligtenberg Journal: Gastric Cancer Date: 2021-04-28 Impact factor: 7.370